EBAG9

Across TCGA pan-cancer cohorts, EBAG9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EBAG9 data layer compared with 15 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EBAG9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EBAG9 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where EBAG9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.648	0.846	.013	21	view →
CCRCC	OS	Tertile	IV	0.150	1.000	.036	12	view →
PDAC	OS	Quartile	All	0.372	0.635	.002	12	view →
LUAD	OS	Quartile	III,IV	0.743	0.227	.006	4	view →
LSCC	DFS	Median	All	0.905	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EBAG9–HNSC (DFS)

Open the HNSC breakdown →